Academic, open label, phase I clinical trial on the use of fresh, allogeneic CD19-CAR T cells for treatment of children with relapsed/refractory B-cell Acute Lymphoblastic Leukemia
responsabile: Giulia Fiscon
data termine: April 2026
finanziamento: Ministero Salute
Istituzioni Italiane